Ketamine in fibromyalgia: a systematic review.

IF 2 4区医学 Q3 RHEUMATOLOGY

Advances in Rheumatology Pub Date : 2024-07-29 DOI:10.1186/s42358-024-00393-9

Jozélio Freire de Carvalho, Eduardo Pondé de Sena

{"title":"Ketamine in fibromyalgia: a systematic review.","authors":"Jozélio Freire de Carvalho, Eduardo Pondé de Sena","doi":"10.1186/s42358-024-00393-9","DOIUrl":null,"url":null,"abstract":"Objective: Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients.Materials and methods: We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021. This study was registered at PROSPERO.Results: There were only 6 articles published in this field, with a total of 115 patients. The female sex was predominant (88 to 100%). The age varied from 23 to 53 years old. Disease duration ranged from 1 month to 28 years. The dosage of ketamine changed from 0.1 mg/kg-0.3-0.5 mg/kg in intravenous infusion (4/5) and subcutaneous application (1/5). Regarding outcomes, the Visual analog scale (VAS) before ketamine was from 59 to 100 mm and after treatment from 2 to 95 mm. Most short-term studies had a good response. Only the study with 8 weeks of follow-up did not observe a good response. Side effects were common; all appeared during the infusion and disappeared after a few minutes of the ketamine injection.Conclusions: The present study demonstrates the effectiveness and safety of ketamine in FM patients in the short term. Although, more studies, including long-term follow-up studies, are still needed.","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"54"},"PeriodicalIF":2.0000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s42358-024-00393-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients.

Materials and methods: We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021. This study was registered at PROSPERO.

Results: There were only 6 articles published in this field, with a total of 115 patients. The female sex was predominant (88 to 100%). The age varied from 23 to 53 years old. Disease duration ranged from 1 month to 28 years. The dosage of ketamine changed from 0.1 mg/kg-0.3-0.5 mg/kg in intravenous infusion (4/5) and subcutaneous application (1/5). Regarding outcomes, the Visual analog scale (VAS) before ketamine was from 59 to 100 mm and after treatment from 2 to 95 mm. Most short-term studies had a good response. Only the study with 8 weeks of follow-up did not observe a good response. Side effects were common; all appeared during the infusion and disappeared after a few minutes of the ketamine injection.

Conclusions: The present study demonstrates the effectiveness and safety of ketamine in FM patients in the short term. Although, more studies, including long-term follow-up studies, are still needed.

查看原文本刊更多论文

氯胺酮治疗纤维肌痛：系统综述。

目的：纤维肌痛（FM）患者接受抗抑郁剂治疗；在大多数情况下，这些药物会失去疗效或产生不良反应。在一些研究中，氯胺酮是一种用于 FM 的麻醉药物。本文旨在系统回顾氯胺酮对纤维肌痛（FM）患者的安全性和有效性：我们系统地检索了 1966 年至 2021 年在 Pubmed 上发表的有关 FM 和氯胺酮的文章。本研究已在 PROSPERO 注册：结果：该领域仅发表了 6 篇文章，共涉及 115 名患者。女性占多数（88%至100%）。年龄从 23 岁到 53 岁不等。病程从 1 个月到 28 年不等。氯胺酮的剂量从0.1毫克/千克-0.3-0.5毫克/千克不等，静脉注射（4/5）和皮下注射（1/5）。在疗效方面，氯胺酮治疗前的视觉模拟量表（VAS）为59至100毫米，治疗后为2至95毫米。大多数短期研究的反应良好。只有一项为期8周的随访研究未观察到良好反应。副作用很常见；所有副作用都出现在输液过程中，并在注射氯胺酮几分钟后消失：本研究表明，氯胺酮在短期内对 FM 患者有效且安全。尽管如此，我们仍需进行更多的研究，包括长期随访研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Rheumatology Medicine-Rheumatology

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

53 weeks

期刊介绍： Formerly named Revista Brasileira de Reumatologia, the journal is celebrating its 60th year of publication. Advances in Rheumatology is an international, open access journal publishing pre-clinical, translational and clinical studies on all aspects of paediatric and adult rheumatic diseases, including degenerative, inflammatory and autoimmune conditions. The journal is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines and letters arising from published material.